Washington, D.C. 20549
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 26, 2020
Tandem Diabetes Care, Inc.
(Exact name of registrant as specified in its charter)
(State or other jurisdiction
of incorporation)
File Number)
(I.R.S. Employer
Identification No.)
11075 Roselle Street
San Diego California
(Zip Code)
(Address of principal executive offices)
 Registrant’s telephone number, including area code: (858366-6900
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of Each ClassSymbolName of Exchange on Which Registered
Common Stock, par value $0.001 per shareTNDMNASDAQ Global Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 

Item 5.02  Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Richard P. Valencia, one of the non-employee directors of Tandem Diabetes Care, Inc. (the "Company"), notified the Company that he intends to commence service as Chairman of the Board and Chief Executive Officer of a privately held company that is developing diabetes-related products. While the Company does not believe Mr. Valencia’s new employer is currently developing insulin delivery technology, due to the potential for his new role to create actual or perceived conflicts of interest between Mr. Valencia and the Company and/or our third-party collaboration partners, the Board of Directors of the Company (the "Board") requested that he resign as a director of the Company. Accordingly, Mr. Valencia tendered his resignation as a director effective May 26, 2020, which has been accepted. Mr. Valencia served on the Board since June 2018. Mr. Valencia did not resign as a result of any disagreement with the Company on any matter relating to its operations, policies or practices. 

Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Number  Description

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Tandem Diabetes Care, Inc.
/s/ David B. Berger
David B. Berger
Executive Vice President, Chief Legal & Compliance Officer
Date: May 27, 2020